Losmapimod - A novel drug against cardiovascular diseases?;Losmapimod: Ein neuartiger Wirkstoff gegen kardiovaskuläre Erkrankungen?

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 1-2, 2013, Pages 39-42

  Dewenter, M ^a   Vettel, C ^a   El Armouche, A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

atherosclerosis; cardiovascular diseases; heart failure; Losmapimod; p38 MAPK; remodeling

Indexed keywords

LOSMAPIMOD; 6 (5 ((CYCLOPROPYLAMINO)CARBONYL) 3 FLUORO 2 METHYLPHENYL) N (2,2 DIMETHYLPRPYL) 3 PYRIDINECARBOXAMIDE; 6-(5-((CYCLOPROPYLAMINO)CARBONYL)-3-FLUORO-2-METHYLPHENYL)-N-(2,2-DIMETHYLPRPYL)-3-PYRIDINECARBOXAMIDE; CYCLOPROPANE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

CARDIOVASCULAR DISEASE; REVIEW; HUMAN;

CARDIOVASCULAR DISEASES; CYCLOPROPANES; HUMANS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84871125856     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1327368     Document Type: Review

References (23)

1. Aston N. M., Bamborough P., Buckton J. B. et al. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem: 2009; 52 6257 6269
2. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. Version 1.5 März: 2012
3. Cheriyan J., Webb A. J., Sarov-Blat L. et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation: 2011; 123 515 523
4. Clark J. E., Sarafraz N., Marber M. S. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther: 2007; 116 192 206 (Pubitemid 47451511)
5. Elkhawad M., Rudd J. H., Sarov-Blat L. et al. Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. JACC Cardiovasc Imaging: 2012; 5 911 922
6. Enbrel® Fachinformation. Pfizer Pharma GmbH Stand Juli 2012.
7. Genovese M. C. Inhibition of p38: has the fat lady sung? Arthritis Rheum: 2009; 60 317 320
8. Ju H., Behm D. J., Nerurkar S. et al. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther: 2003; 307 932 938 (Pubitemid 37494209)
9. Kaiser R. A., Lyons J. M., Duffy J. Y. et al. Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia- reperfusion. Am J Physiol Heart Circ Physiol: 2005; 289 H2747 H2751 (Pubitemid 41698592)
10. Kardakaris R., Gareus R., Xanthoulea S. et al. Endothelial and macrophage-specific deficiency of P38α MAPK does not affect the pathogenesis of atherosclerosis in ApoE-/- mice. PLoS One: 2011; 6 e21055
11. Kerkela R., Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy? J Am Coll Cardiol: 2006; 48 556 558
12. Kumphune S., Chattipakorn S., Chattipakorn N. Role of p38 inhibition in cardiac ischemia/reperfusion injury. Eur J Clin Pharmacol: 2012; 68 513 524
13. Kwon H. J., Coté T. R., Cuffe M. S. et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med: 2003; 138 807 811
14. Lomas D. A., Lipson D. A., Miller B. E. et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol: 2012; 52 416 424
15. Marber M. S., Rose B., Wang Y. The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol: 2011; 51 485 490
16. Mei S., Gu H., Ward A. et al. p38 Mitogen-activated Protein Kinase (MAPK) Promotes Cholesterol Ester Accumulation in Macrophages through Inhibition of Macroautophagy. J Biol Chem: 2012; 287 11761 11768
17. Olzinski A. R., McCafferty T. A., Zhao S. Q. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc Res: 2005; 66 170 178 (Pubitemid 40357880)
18. Remicade® Fachinformation. MSD Sharp & Dohme GmbH Stand März 2012.
19. Seeger F. H., Sedding D., Langheinrich A. C. et al. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol: 2010; 105 389 397
20. Statistisches Bundesamt Diagnosedaten der Patienten und Patientinnen in Krankenhäusern. (einschl. Sterbe- und Stundenfälle) - Fachserie 12 Reihe 6.2.1 - 2010.
21. US National Institutes of Health Clinical trials. http://www. clinicaltrials.gov/ct2/results?term=GW856553 Letzter Zugriff 30.10.2012.
22. WHO Cardiovascular diseases (CVDs). Fact sheet No 317. September 2012 http://www.who.int/mediacentre/factsheets/fs317/en/index.html Letzter Zugriff 30.10.2012.
23. Willette R. N., Eybye M. E., Olzinski A. R. et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther: 2009; 330 964 970